Related Experiment Video
Updated: Mar 6, 2026

08:31
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
910
Possible novel agents in marginal zone lymphoma
Pier Luigi Zinzani1, Alessandro Broccoli1
1Institute of Haematology "L. e A. Seràgnoli", Via Massarenti, 9, 40138 Bologna, Italy.
Best Practice & Research. Clinical Haematology
|March 15, 2017
Summary
Novel agents show promise for marginal zone lymphoma. This review covers lenalidomide, bortezomib, and targeted therapies, offering insights into efficacy and safety for nodal and extranodal presentations.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Marginal zone lymphoma (MZL) encompasses nodal, extranodal, and splenic subtypes.
- Treatment options for MZL have evolved, necessitating a review of novel therapeutic agents.
Purpose of the Study:
- To review the efficacy, safety, and mechanisms of action of novel agents in marginal zone lymphoma.
- To discuss targeted agents and emerging drugs for indolent non-Hodgkin's lymphomas.
Main Methods:
- Literature review of clinical trials and relevant experiences.
- Focus on data from trials specifically designed for marginal zone lymphoma patients.
- Inclusion of data on lenalidomide, bortezomib, 90yttrium-ibrutumomab tiuxetan, obinutuzumab, ibrutinib, idelalisib, venetoclax, copanlisib, ublituximab, and TGR-1202.
Main Results:
- Lenalidomide, bortezomib, and 90yttrium-ibrutumomab tiuxetan have demonstrated efficacy in MZL.
- Targeted agents and newer drugs show potential, particularly in the context of indolent non-Hodgkin's lymphomas.
- Drug combinations and ongoing trials offer future therapeutic avenues.
Conclusions:
- Novel agents represent a significant advancement in marginal zone lymphoma treatment.
- Further research into drug combinations and new therapies is warranted.
- Personalized treatment strategies are emerging for nodal and extranodal MZL.
Keywords:
BTKBortezomibClinical trialCopanlisibIbritumomab tiuxetanIbrutinibIdelalisibLenalidomideMarginal zone lymphomaObinutuzumabPI3KRadioimmunotherapyRituximabTGR-1202UblituximabVenetoclaxMore Related Videos
Related Concept Videos
Primary Lymphoid Organs
16.3K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
16.3K
Secondary Lymphoid Organs
9.9K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
9.9K
Lymphoid Cells and Tissues
3.6K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
3.6K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Differentiation of Common Myeloid Progenitor Cells
4.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.1K

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)